[Tranexamic acid in orthopedic surgery].

Abstract

Perioperative bleeding may require blood transfusions, which are sometimes not without complications and risks, with the subsequent increase in health care costs. Among other prevention methods, treatment with tranexamic acid (ATX) has shown to be effective in reducing surgical blood loss, especially in the immediate postoperative period. In this regard, studies evaluating ATX in orthopedic surgery show that it is effective and safe when administered intravenously or intra-articularly. The usual evaluated intravenous doses range between 10mg/Kg and 20mg/kg or a fixed dose of 1g to 2g; while intra-articularly, it varies between 250 mg and 3g. ATX, as an anti-fibrinolytic has a potential thrombotic effect, thus it is contraindicated in those patients at risk or with a history of thrombosis. Its topical administration may be safer, but studies are needed to confirm this.

• Authors: X Aguilera-Roig, M Jordán-Sales, L Natera-Cisneros, J C Monllau-García, M J Martínez-Zapata
• Journal: Revista espanola de cirugia ortopedica y traumatologia (Rev Esp Cir Ortop Traumatol) 2014 Jan-Feb Vol. 58 Issue 1 Pg. 52-6 ISSN: 1988-8856 [Electronic] Spain
• Vernacular Title: Ácido tranexámico en cirugía ortopédica.
• PMID: 24126146 (Publication Type: English Abstract, Journal Article, Review)
• Copyright: Copyright © 2013 SECOT. Published by Elsevier Espana. All rights reserved.

Chemical References

• Antifibrinolytic Agents
• Tranexamic Acid

Topics

• Antifibrinolytic Agents (therapeutic use)
• Blood Loss, Surgical (prevention & control)
• Humans
• Orthopedic Procedures
• Tranexamic Acid (therapeutic use)